| |
Audit
|
Compensation
|
Nominating and Corporate Governance
|
Science and Technology
|
Peter J. Crowley
 
|
|
|
|
|
 Chairman of the Board Peter J. Crowley retired in 2008 from a 23-year career at CIBC World Markets, where he headed Healthcare Investment Banking since 1995, with responsibility for public and private financing and advisory services for biotechnology, pharmaceutical, medical device and healthcare services companies. While at CIBC, Mr. Crowley worked in the mergers and acquisitions group, the principal investments group and for the last 14 years had been head of healthcare investment banking. Mr. Crowley's early professional experience was with Allen and Company and Blyth Eastman Paine Webber.
Mr. Crowley serves on the boards of the New York Eye and Ear Infirmary, the Cancer Research Institute, the Foundation Fighting Blindness, the Glaucoma Foundation, and Rye Country Day School. He is also a board member at Jurlique plc, a skin care company, and Napastyle, a specialty food and furnishings company. Peter is active as a committee member of the Harvard Alumni Association and member of the Council of Rockefeller University. In addition to a Harvard undergraduate degree in economics, he holds an M.B.A. in finance from Columbia University's Graduate School of Business.
|
|
Paul J. Maddon M.D., Ph.D.
|
|
|
|
|
 Vice Chairman Dr. Maddon is Progenics' founder and has served in various capacities including chairman of the board, chief executive officer, president and chief science officer. A molecular virologist and immunologist by training, he has made seminal contributions to understanding viral entry and infection. Dr. Maddon serves as chair of the advisory committee of The Rockefeller University's Science Outreach Program and is a member of Rockefeller's University Council and the Bridges to Better Medicine Committee. Dr. Maddon serves as a trustee of Columbia University and is a member of the advisory committee of Columbia's Science Honors Program. At Columbia, Dr. Maddon was graduated summa cum laude with a B.A. in biochemistry and was elected to Phi Beta Kappa. He received an M.D. from Columbia's College of Physicians and Surgeons and a Ph.D. in biochemistry and molecular biophysics from its Graduate School of Arts and Sciences.
|
|
Charles A. Baker
|
|
|
|
|
 Charles A. Baker is a business advisor to biotechnology companies. He is the former Chairman, President and Chief Executive Officer of The Liposome Company, Inc., a biotechnology company located in Princeton, New Jersey, a position he held from 1989 until his retirement in 2000. Mr. Baker is currently a director of Regeneron Pharmaceuticals, Inc., a biotechnology company. Mr. Baker has 42 years of pharmaceutical industry experience and has held senior management positions at Pfizer, Abbott Laboratories and Squibb Corporation. Mr. Baker received a B.A. from Swarthmore College and a J.D. from Columbia University.
|
|
Mark R. Baker
|
|
|
|
|
 Mr. Baker joined Progenics in 2005 as senior vice president and general counsel and secretary, and has since served as executive vice president, president, and was appointed to the board of directors. Mr. Baker began his career in 1979 as a corporate lawyer with the law firm Dewey Ballantine in New York, where he was a partner and co-chairman of the capital markets group, among other positions, until 1997. From 1997 to 2001, he served ContiGroup Companies, Inc. (formerly Continental Grain Company), a privately held international agri-business and financial concern, as executive vice president, chief legal officer and secretary. Mr. Baker was chief business officer, secretary and a director of New York Water Taxi, a privately held passenger ferry operation, from 2003 to 2005. He holds an A.B. degree from Columbia College and a J.D. from the Columbia University School of Law.
|
|
Kurt W. Briner
|
|
|
|
|
 Kurt W. Briner is the former President and Chief Executive Officer of Sanofi Pharma S.A. in Paris, France, a position he held from 1988 until his retirement in 2000, and he has nearly 32 years' experience in the pharmaceutical industry. Mr. Briner is currently also a director of Novo Nordisk Danmark and Galenica S.A., each a European-based pharmaceutical company. He attended Humanistisches Gymnasium in Basel and Ecole de Commerce in Basel and Lausanne.
|
|
Mark F. Dalton
|
|
|
|
|
 Mark F. Dalton has been the President and a director of Tudor Investment Corporation, an investment advisory company, and its affiliates since 1988, and has been the President and Vice Chairman of such companies since 2005. From 1979 to 1988, he served in various senior management positions at Kidder, Peabody & Co. Incorporated, including Chief Financial Officer. Mr. Dalton is currently a director of several private companies. Mr. Dalton received a B.A. from Denison University and a J.D. from Vanderbilt University Law School.
|
|
Stephen P. Goff Ph.D.
|
|
|
|
|
 Stephen P. Goff, Ph.D. has been a member of our Virology Scientific Advisory Board since 1988 and has been its Chairman since April 1991. Dr. Goff has been the Higgins Professor in the Departments of Biochemistry and Microbiology at Columbia University since June 1990. He received an A.B. in biophysics from Amherst College and a Ph.D. in biochemistry from Stanford University. Dr. Goff performed post-doctoral research at the Massachusetts Institute of Technology in the laboratory of Dr. David Baltimore.
|
|
David A. Scheinberg M.D., Ph.D.
|
|
|
|
|
 David A. Scheinberg, M.D., Ph.D. has been a member of our Cancer Scientific Advisory Board since 1994. Dr. Scheinberg has been associated with Sloan-Kettering since 1986, where he is the Vincent Astor Chair and Member, Leukemia Service; Chairman, Molecular Pharmacology and Chemistry Program; Chairman, Experimental Therapeutics Center; Member, Clinical Immunology Service; and Head, Laboratory of Hematopoietic Cancer Immunochemistry. He also holds the position of Professor of Medicine and Pharmacology, Weill-Cornell Medical College. He received a B.A. from Cornell University and an M.D. and a Ph.D. in pharmacology and experimental therapeutics from The Johns Hopkins University School of Medicine.
|
|
Nicole S. Williams M.B.A.
|
|
|
|
|
 Ms. Williams served as Executive Vice President and Chief Financial Officer of Abraxis Bioscience, Inc. a biopharmaceutical company (formerly American Pharmaceuticals Partners, Inc.). Previously, Ms. Williams was Executive Vice President and Chief Financial Officer of R.P. Scherer Corporation, a leading drug delivery company. She earned her MBA from the University of Chicago, as well as a Master of Science in International Affairs and her undergraduate degree from the Université de Genève. Ms. Williams also serves on the Board of Directors and is Audit Chair for Orchid Cellmark, Inc.
|
You may submit your communication anonymously or confidentially by postal mail. You may also indicate whether you are a shareholder, customer, supplier, or other interested party. Communications are distributed to the Board, or to any individual directors as appropriate, depending on the facts and circumstances outlined in the communication. Material that is unduly hostile, threatening, illegal or similarly unsuitable will be excluded, with the provision that any communication that is filtered out must be made available to any non-management director upon request.
